Related Experiment Video
Updated: Jun 21, 2026
Global Identification of Co-Translational Interaction Networks by Selective Ribosome Profiling
Published on: October 7, 2021
Cost effective analysis of ribosome-component immune modulation
Alessandro Fiocchi1, Dario Olivieri, Sergio Marcassa
1Department of Child and Maternal Medicine, Melloni Hospital, Milan, Italy.
Insights
Ribosomal immunotherapy can significantly reduce healthcare costs associated with recurrent respiratory infections in children. This immune modulator offers economic benefits by decreasing treatment expenses and improving productivity.
Area of Science:
- Pediatrics
- Immunology
- Health Economics
Background:
- Recurrent airway infections are a leading cause of pediatric medical visits and hospitalizations, incurring substantial healthcare costs.
- The use of ribosomal bacterial vaccines and membrane fractions is often limited to prevention, despite proven efficacy and safety for treatment.
- Economic impact of recurrent respiratory infections includes direct medical costs and indirect productivity losses.
Purpose of the Study:
- To analyze the economic benefits of using ribosomal immunotherapy for recurrent respiratory infections.
- To evaluate the cost-effectiveness of immune modulators derived from bacterial components.
Main Methods:
- A literature review of pharmacoeconomic studies was conducted.
- Analysis focused on economic parameters related to the use of ribosome component immune modulators.
- Included direct and indirect cost considerations for recurrent respiratory infections.
Main Results:
- Ribosomal immunotherapy demonstrates the capability to reduce expenditures for recurrent respiratory infection treatment.
- Significant savings are achievable in terms of direct costs, time, and productivity loss.
- The initial investment in prevention through immunotherapy is offset by long-term savings due to reduced disease recurrence.
Conclusions:
- Ribosomal immunotherapy offers a cost-effective strategy for managing recurrent respiratory infections in children.
- Integrating the costs of treatment and productivity losses highlights the economic advantages of this therapeutic approach.
- Primary care physicians should consider both direct and indirect costs when evaluating treatment options for chronic respiratory infections.
Abstract:
In childhood, recurrent airway infections are the most common cause for medical visits and hospitalizations. Their economic impact is considerable and their treatment accounts for a substantial quota of the health care budget. Despite documented efficacy and safety, ribosomal bacterial vaccine and membrane fraction use is still limited by being prevalently considered for prevention rather than treatment. The objective of this study was to analyze the economic benefit achieved with ribosomal immunotherapy. A review was performed of available literature data on economic parameters. Pharmacoeconomic studies published during the past few years showed how the use of ribosome component immune modulator is capable of reducing expenditure associated with treatment of recurrent respiratory infection and allows achievement of substantial savings in terms of cost, time, and loss of productivity. The initial cost of prevention in patients suffering from chronic respiratory infections is offset by a subsequent saving arising from less recurrence of disease. Direct management costs such as therapy courses, medical visits, medical exams, hospitalizations, etc., and indirect costs such as absence from school and work are not routinely considered by primary care physicians.
Related Concept Videos
02:24Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique helps...
02:28Leaky Scanning